TY - JOUR
T1 - Elevated soluble CD30 characterizes patients with hepatitis C virus-induced liver allograft cirrhosis
AU - Bharat, Ankit
AU - Narayanan, Kishore
AU - Golocheikine, Anjali
AU - Steward, Nancy
AU - Crippin, Jeffrey
AU - Lisker-Melman, Mauricio
AU - Shenoy, Surendra
AU - Lowell, Jeffrey
AU - Chapman, William C.
AU - Mohanakumar, Thalachallour
PY - 2007/12
Y1 - 2007/12
N2 - Hepatitis C virus (HCV) recurrence after orthotopic liver transplantation (OLT) significantly accelerates progression to allograft cirrhosis. Current biochemical parameters to monitor progression of chronic HCV after OLT have yielded low specificity and sensitivity. Here we investigated the HCV-specific immunity and serum levels of soluble CD30 (sCD30), a novel marker of Th2 immunity, in patients with and without allograft cirrhosis. Patients with hepatic inflammation but no cirrhosis (HIN, n=20) revealed elevated serum interferon (IFN)-γ and high frequency of IFN-γ producing CD4 T(h1) cells compared to those with hepatic cirrhosis (HFC, n=20) that had high interleukin (IL)-5 and IL-5 producing CD4 T(h2) cells. Patients with HFC, but not HIN, were found to have significantly higher levels of sCD30. Therefore, we conclude that lack of optimal Th1-type CD4 T cells is associated with HCV-induced allograft cirrhosis. Further, sCD30 may represent a novel marker for surveillance of hepatic cirrhosis in transplant recipients with chronic HCV infection.
AB - Hepatitis C virus (HCV) recurrence after orthotopic liver transplantation (OLT) significantly accelerates progression to allograft cirrhosis. Current biochemical parameters to monitor progression of chronic HCV after OLT have yielded low specificity and sensitivity. Here we investigated the HCV-specific immunity and serum levels of soluble CD30 (sCD30), a novel marker of Th2 immunity, in patients with and without allograft cirrhosis. Patients with hepatic inflammation but no cirrhosis (HIN, n=20) revealed elevated serum interferon (IFN)-γ and high frequency of IFN-γ producing CD4 T(h1) cells compared to those with hepatic cirrhosis (HFC, n=20) that had high interleukin (IL)-5 and IL-5 producing CD4 T(h2) cells. Patients with HFC, but not HIN, were found to have significantly higher levels of sCD30. Therefore, we conclude that lack of optimal Th1-type CD4 T cells is associated with HCV-induced allograft cirrhosis. Further, sCD30 may represent a novel marker for surveillance of hepatic cirrhosis in transplant recipients with chronic HCV infection.
KW - Hepatitis C virus
KW - Liver transplantation
KW - Soluble CD30
UR - http://www.scopus.com/inward/record.url?scp=37549039499&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=37549039499&partnerID=8YFLogxK
U2 - 10.1097/01.tp.0000295973.31877.7b
DO - 10.1097/01.tp.0000295973.31877.7b
M3 - Article
C2 - 18165785
AN - SCOPUS:37549039499
SN - 0041-1337
VL - 84
SP - 1704
EP - 1707
JO - Transplantation
JF - Transplantation
IS - 12
ER -